Immunotherapy plus PARP inhibitor for HR+ HER2- advanced breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy (adebrelimab) and a PARP inhibitor (fluzoparib) for women with HR+, HER2- advanced breast cancer that has a specific genetic feature called HRD positivity. It may offer a new option if standard hormone therapy and limited chemotherapy haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer is HR+ (hormone receptor positive) and HER2- (negative).
- Your tumor has a high level of genomic instability (HRD positive) or a BRCA mutation.
- Your cancer has spread or cannot be cured by surgery.
- You have had at least one prior endocrine therapy (like a CDK4/6 inhibitor) and no more than one prior chemotherapy for advanced disease.
- You have not had prior treatment with a PD-1/PD-L1 inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for people with advanced HR+ HER2- breast cancer whose cancer has progressed on a CDK4/6 inhibitor. It uses a special molecular test to match you to the targeted therapy most likely to work.
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests a combination of two drugs (QL1706 and olaparib) for people with advanced breast cancer that is HER2-negative and has a specific DNA repair problem called HRD. It's for those who have already tried 2 to 4 previous treatments.
Hear when a new Female Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.